Biodesix (BDSX) Q4 2022: Core Lung Diagnostics Revenue Jumps 57% as Test Adoption Accelerates
Biodesix’s core lung diagnostics business delivered a 57% revenue surge in 2022, powered by expanded reimbursement and sharply higher test volumes, even as COVID testing faded out of the model. The company’s focus on commercial execution, payer coverage, and clinical data generation is translating into greater market access and improved gross margins, while biopharma services backlog signals future upside. With a strengthened balance sheet and robust guidance, Biodesix is positioned to capitalize on its five-test portfolio and emerging AI-driven diagnostics tailwinds in 2023.
Summary
- Core Portfolio Penetration: Biodesix’s lung diagnostics tests are gaining share as payer coverage expands.
- Margin Expansion: Shift away from COVID testing and operational scale are driving gross margin improvement.
- Biopharma Backlog: Record contracted services set up a stronger second half and 2024 tailwind.
Business Overview
Biodesix is a precision diagnostics company focused on lung disease, generating revenue through proprietary blood-based tests that guide risk assessment, treatment, and monitoring for lung cancer patients. Its business operates two main segments: the core lung diagnostics portfolio (Notify Lung and IQ Lung, five tests in total, all covered by Medicare) and biopharmaceutical services (contracted testing and data analysis for drug developers). The company’s revenue model is driven by test adoption, payer reimbursement, and partnership contracts, with the core lung diagnostics segment now representing the vast majority of revenue as COVID testing winds down.
Performance Analysis
Biodesix’s core lung diagnostics business posted 57% revenue growth in 2022, driven by a 54% increase in test volumes and broadening reimbursement coverage, including new Medicare and private payer wins for the Notify XL2 and Notify CDT tests. The company’s five-test portfolio, which provides both nodule risk assessment and post-diagnosis treatment guidance, has seen especially strong adoption in Notify Lung, where volumes have quadrupled over two years. Notably, these gains were achieved as COVID testing revenue declined to negligible levels, underscoring the transition to a higher-quality, recurring revenue base.
Gross margins expanded to 66% in Q4 and 63% for the year, up from 44% in 2021, reflecting the shift toward high-margin diagnostics and away from low-margin COVID testing. Operating expenses rose, primarily from commercial team expansion and higher travel costs as sales access normalized post-pandemic. The company ended the year with $43.1 million in cash, bolstered by a $37.9 million equity raise and new debt financing, offset by debt extinguishment and a $4 million one-time charge. Biopharmaceutical services revenue was flat year-over-year but exited with a record $9.2 million under contract, positioning this segment for a stronger contribution in late 2023.
- Test Volume Surge: Core lung diagnostics volumes rose 61% YoY in Q4, with Notify Lung the main driver.
- Gross Margin Upside: Margin improvement reflects the mix shift to proprietary tests and expanded payer coverage.
- Biopharma Services Variability: Revenue remains lumpy but backlog growth signals a ramp in the second half.
The company’s financials now reflect a clear pivot to its core business, with recurring, high-margin diagnostics revenue powering growth and margin expansion, while biopharma services provide optionality for future upside.
Executive Commentary
"In 2022, we experienced a significant increase in adoption of our core lung diagnostics business, growing test volume by 54% and revenue 57% year over year. In fact, our notified lung testing volumes have more than quadrupled over the last two years."
Scott Hutton, Chief Executive Officer
"Looking into 2023, we expect the overall gross margin percentage to continue to increase as a result of several factors, including the benefit of the Medicare coverage for Notify CDT tests, the benefit of recently announced commercial payer coverage decisions for Notify XL2, as well as additional commercial coverage as we move through the year."
Robin Harper-Cowie, Chief Financial Officer
Strategic Positioning
1. Commercial Expansion and Payer Coverage
Biodesix’s salesforce returned to full field access, unlocking accelerated adoption of its five-test portfolio, especially in regions with high lung cancer incidence. New Medicare and private payer wins for Notify XL2 and Notify CDT expanded the addressable market by millions of covered lives, with additional coverage anticipated in 2023. Broader reimbursement is a central growth lever, with recent wins expected to contribute more meaningfully this year.
2. Clinical Validation and Data Generation
Investment in clinical utility data remains a core differentiator, supporting both commercial adoption and payer negotiations. Recent studies, such as INSIGHT and Altitude, are deepening evidence for test efficacy and could serve as inflection points for further adoption, especially if interim analyses are positive later in 2023.
3. Biopharma Services as Growth Optionality
The biopharmaceutical services segment, which provides contract testing and data analytics for drug developers, ended the year with a record $9.2 million in backlog. While revenue recognition is lumpy, the mix of large and small pharma partners, and both prospective and retrospective studies, sets up for a stronger second half and 2024 tailwind.
4. AI and Multi-Omic Platform Development
Biodesix’s decade-plus investment in AI and machine learning for diagnostics underpins its multi-omic platform, which integrates genomics, proteomics, and now radiomics. The company believes this capability will be critical for future personalized medicine and is actively collaborating to stay at the forefront of AI-driven diagnostic innovation.
5. Cost Discipline and Resource Allocation
Management is prioritizing near-term revenue drivers and has levers to flex investment up or down, depending on the pace of commercial uptake and biopharma services growth. Clinical studies with slow enrollment are being paused or reevaluated to optimize capital efficiency.
Key Considerations
The quarter marks a pivotal shift for Biodesix, with its diagnostics business scaling, margins rising, and payer coverage broadening. The company is executing on multiple fronts to drive sustainable, high-quality growth.
Key Considerations:
- Reimbursement Leverage: Recent and pending private payer wins could materially expand the revenue base in 2023 and beyond.
- Clinical Evidence Pipeline: Studies like Altitude and INSIGHT have the potential to unlock further adoption and payer support.
- Backlog Monetization: Biopharma services backlog is at a record, but timing of revenue recognition remains variable.
- Cash Burn Management: Management is closely monitoring spend and has flexibility to adjust investments as market conditions evolve.
- AI Differentiation: Longstanding AI and machine learning expertise positions Biodesix to lead in multi-omic, personalized diagnostics.
Risks
Biodesix faces execution risk in commercial adoption and payer coverage expansion, with delays in clinical study enrollment and biopharma project timing introducing revenue variability. Cash burn remains a focus, though management has levers to adjust spend if growth does not materialize as projected. Competition in diagnostics and evolving reimbursement landscapes could also pressure future growth or margins.
Forward Outlook
For Q1 2023, Biodesix guided to:
- Continued strong growth in core lung diagnostics test volumes and revenue
- Negligible contribution from COVID testing
For full-year 2023, management guided:
- Total revenue of $52 million to $55 million, representing approximately 60% YoY growth in core business
Management highlighted several factors that underpin this outlook:
- Broader reimbursement and commercial team expansion driving test adoption
- Biopharma services revenue expected to ramp in the second half as backlog is executed
Takeaways
Biodesix’s Q4 and 2022 results confirm a strategic pivot to high-margin, recurring diagnostics revenue, supported by payer wins and strong commercial execution. The record biopharma backlog and ongoing clinical data pipeline provide additional growth levers for 2023 and beyond.
- Core Diagnostics Momentum: Rapid test adoption and payer expansion are driving sustainable, high-quality growth.
- Operational Flexibility: Management is actively managing spend and resource allocation to balance growth and cash preservation.
- Future Watchpoint: Monitor Altitude and INSIGHT study readouts, biopharma backlog conversion, and further payer coverage wins as catalysts for upside or risk to guidance.
Conclusion
Biodesix enters 2023 with a strengthened commercial engine, expanding reimbursement, and a robust balance sheet, positioning it to capture further share in the lung diagnostics market. The company’s strategic focus on clinical validation, payer coverage, and operational discipline sets up a compelling growth narrative, though execution on backlog conversion and clinical milestones will be key to sustaining momentum.
Industry Read-Through
Biodesix’s transition away from COVID testing and toward high-margin, multi-omic diagnostics mirrors a broader industry pivot, as diagnostics companies seek to anchor revenue in proprietary, reimbursed platforms. Rapid payer coverage expansion and AI-driven test development are emerging as competitive differentiators, with clinical utility data increasingly critical for market access. The lumpy nature of biopharma services revenue is an industry-wide theme, but record backlogs suggest pent-up demand as pharma R&D normalizes post-pandemic. Investors should watch for similar reimbursement and AI adoption trends across diagnostics peers, as well as the impact of clinical study progress on commercial inflection points.